Eli Lilly’s newest weight-loss drug developments in 2026 include the FDA-approved oral medication Foundayo (orforglipron), encouraging Phase 3 results for investigational retatrutide, and new clinical data for the experimental combination EloraTZP. The latest announcement, published on November 9, 2026, revealed that Foundayo significantly reduced obstructive sleep apnea severity in adults with obesity or overweight.
The findings reflect a broader change in obesity research. Pharmaceutical companies are investigating not only body-weight reduction, but also related conditions involving metabolism, blood glucose, cardiovascular risk factors, and sleep-disordered breathing.
Eli Lilly’s development pipeline currently includes medicines that activate different hormone receptors, including GLP-1, GIP, glucagon, and amylin receptors.
But what is the newest Eli Lilly weight-loss drug, how does it work, and what do the latest clinical trials reveal?
This article examines Eli Lilly’s latest weight-loss medications in 2026, including their clinical results, mechanisms of action, regulatory status, and ongoing research.
Last updated: November 10, 2026.
November 9, 2026: Eli Lilly Announces New Foundayo Trial Results
On November 9, 2026, Eli Lilly announced positive Phase 3 findings from its ATTAIN-OSA clinical research program.
The studies evaluated Foundayo (orforglipron), an oral GLP-1 receptor agonist, in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight.
Obstructive sleep apnea is a condition in which breathing repeatedly stops or becomes shallow during sleep. It can contribute to disrupted sleep and is associated with increased cardiovascular risk.
The ATTAIN-OSA program included 712 randomized participants across two studies:
- Study 1: 363 participants who were unable or unwilling to use positive airway pressure (PAP) therapy.
- Study 2: 349 participants who were already using PAP therapy.
After 52 weeks, the studies reported significant improvements in sleep apnea severity and body weight.
Latest Foundayo Clinical Results
| Clinical outcome | Without PAP therapy | With PAP therapy |
|---|---|---|
| Mean reduction in breathing interruptions | 43.8% | 27.5% |
| Average body-weight reduction | 11.5% | 11.2% |
| Average weight reduction | 28.0 lb | 28.2 lb |
| Reduction in sleep apnea-related oxygen burden | 55.9% | 45.8% |
| Participants achieving remission or mild disease | 31.5% | 19.6% |
These results refer to the Foundayo treatment groups and should be interpreted alongside the corresponding placebo results.
Importantly, the findings were published in the peer-reviewed medical journal JAMA on November 9, 2026.
The study provides new evidence concerning orforglipron’s potential effects beyond body weight alone.
Published study: Orforglipron for Obstructive Sleep Apnea: Results From Two Randomized Clinical Trials
Eli Lilly announcement: Foundayo Phase 3 ATTAIN-OSA Results — November 9, 2026
What Is Foundayo (Orforglipron)?
Foundayo is the brand name for orforglipron, an oral small-molecule GLP-1 receptor agonist developed by Eli Lilly.
Unlike injectable GLP-1-based drugs, Foundayo is administered as a once-daily tablet.
It activates the GLP-1 receptor, which participates in several metabolic processes, including insulin signaling, appetite regulation, and glucose homeostasis.
An important scientific distinction is that orforglipron is not a peptide. It is a non-peptide small molecule designed to activate a receptor that is also targeted by certain peptide-based drugs.
The distinction matters for understanding molecular structure, drug development, and pharmaceutical formulation.
When Was Foundayo FDA Approved?
On April 1, 2026, the U.S. Food and Drug Administration approved Foundayo for chronic weight management in adults with obesity or adults with overweight who have at least one weight-related medical condition.
The approval applies when Foundayo is used alongside a reduced-calorie diet and increased physical activity.
The FDA decision was based on the clinical evidence submitted for its weight-management indication.
Foundayo became commercially available in the United States in April 2026.
However, the new obstructive sleep apnea findings do not mean the medication is already FDA-approved specifically for that condition.
Eli Lilly stated on November 9 that it planned to seek FDA approval for the additional sleep apnea indication by the end of 2026.
Official FDA announcement: FDA Approves Foundayo (Orforglipron) — April 1, 2026
How Does Eli Lilly’s New Oral Weight-Loss Drug Work?
Orforglipron acts on the glucagon-like peptide-1 receptor, commonly called GLP-1R.
GLP-1 is a hormone involved in coordinating metabolic responses after food intake.
Activation of this receptor can influence:
- Glucose-dependent insulin secretion.
- Appetite and food-intake regulation.
- Gastric function.
- Blood glucose control.
- Metabolic signaling in multiple tissues.
Orforglipron’s non-peptide molecular structure distinguishes it from injectable peptide-based GLP-1 therapies.
Its oral formulation also represents a different drug-delivery approach.
Foundayo can be taken without the food and water restrictions associated with some other oral GLP-1 formulations, according to its approved prescribing information.
These pharmaceutical characteristics are relevant to the broader development of oral metabolic medicines.
What Were the Original Foundayo Weight-Loss Trial Results?
Before receiving FDA approval, Foundayo was evaluated in the Phase 3 ATTAIN clinical program.
In the ATTAIN-1 study, adults with obesity or overweight and a weight-related medical condition were assigned to different orforglipron treatment groups or placebo.
At the primary assessment, Eli Lilly reported that participants receiving the highest investigated dose experienced average weight reductions of approximately 27 pounds.
The findings supported the drug’s regulatory submission and subsequent approval.
The November 2026 ATTAIN-OSA results now add a separate body of evidence examining obesity-associated sleep apnea.
It is important not to combine weight-loss percentages from different trials as though they represent a single study population.
Reference: Eli Lilly — Foundayo FDA Approval and ATTAIN-1 Findings
Retatrutide: Eli Lilly’s Investigational Triple-Receptor Drug
Although Foundayo is Lilly’s newly approved oral weight-loss medicine, retatrutide is another major part of its obesity research pipeline.
Retatrutide, also known as LY3437943, is an investigational peptide that activates three hormone receptors:
- GLP-1 receptor.
- GIP receptor.
- Glucagon receptor.
Because of this mechanism, researchers describe retatrutide as a triple hormone receptor agonist.
Its receptor activity is different from orforglipron, which targets GLP-1 receptors.
October 28, 2026: Retatrutide vs. Ozempic Results
On October 28, 2026, Eli Lilly announced results from TRANSCEND-T2D-2, a Phase 3 study comparing investigational retatrutide with semaglutide 2 mg, marketed as Ozempic.
The study involved 1,298 adults with type 2 diabetes.
At 80 weeks, Eli Lilly reported the following results:
| Outcome | Retatrutide 9 mg | Retatrutide 12 mg | Semaglutide 2 mg |
|---|---|---|---|
| Mean body-weight reduction | 19.5% | 20.9% | 9.4% |
| Mean A1C reduction | 2.2 percentage points | 2.2 percentage points | 1.8 percentage points |
The findings were reported under the trial’s efficacy estimand.
Lilly stated that retatrutide achieved statistically greater reductions in A1C and body weight than the comparator in this specific study.
However, the results were company-announced findings and should not be treated as evidence that retatrutide has received regulatory approval.
As of November 10, 2026, retatrutide remains investigational and is not FDA-approved.
Official source: Eli Lilly — Retatrutide vs. Ozempic Phase 3 Results
For additional research coverage, explore Neuro Peptide’s educational resources concerning retatrutide and metabolic receptor signaling.
EloraTZP: Another New Eli Lilly Weight-Loss Drug Under Development
On September 30, 2026, Eli Lilly announced results from a Phase 2b study evaluating EloraTZP, an investigational combination of eloralintide and tirzepatide.
Unlike retatrutide, which is one molecule targeting three receptors, EloraTZP combines two pharmaceutical components.
Eloralintide is an investigational selective amylin receptor agonist.
Tirzepatide activates GIP and GLP-1 receptors and is already used in approved pharmaceutical products.
Together, these components are designed to target three complementary hormonal pathways:
- Amylin.
- GIP.
- GLP-1.
EloraTZP Phase 2b Results
The Phase 2b study enrolled 367 adults with obesity or overweight and type 2 diabetes.
After 48 weeks, Eli Lilly reported average weight reductions of up to 23.3% in an EloraTZP group, compared with 14.8% in the tirzepatide 15 mg comparator group.
The company also reported average A1C reductions of up to 2.9 percentage points with the combination, compared with 2.4 percentage points for tirzepatide.
These findings suggest that combining amylin and incretin receptor activity warrants further clinical investigation.
However, Phase 2b results are not sufficient for regulatory approval, and the findings require confirmation through larger studies.
Lilly announced plans to initiate Phase 3 research during the fourth quarter of 2026.
Official source: Eli Lilly — EloraTZP Phase 2b Results, September 30, 2026
Foundayo vs. Retatrutide vs. EloraTZP
These three developments involve different scientific approaches and regulatory stages.
| Feature | Foundayo | Retatrutide | EloraTZP |
|---|---|---|---|
| Active compound | Orforglipron | LY3437943 | Eloralintide + tirzepatide |
| Molecular category | Non-peptide small molecule | Peptide | Peptide-based combination |
| Receptor pathways | GLP-1 | GLP-1, GIP, glucagon | Amylin, GLP-1, GIP |
| Administration studied | Oral | Injection | Injection |
| Development status | FDA-approved for weight management | Investigational, Phase 3 | Investigational, Phase 2b completed |
| Major 2026 update | New sleep apnea findings | Head-to-head Phase 3 results | Combination trial results |
These compounds have not all been compared directly in the same clinical trial.
Differences in study design, participant characteristics, and follow-up periods prevent reliable conclusions about their overall comparative effectiveness or safety from these separate datasets.
What Are the Side Effects of Eli Lilly’s New Weight-Loss Drugs?
Clinical studies of GLP-1-related treatments commonly report gastrointestinal adverse events.
In the November 2026 ATTAIN-OSA program, the most frequently reported adverse events associated with Foundayo included:
- Nausea.
- Diarrhea.
- Constipation.
- Indigestion.
- Vomiting.
The safety profile was generally consistent with earlier studies of orforglipron.
Nevertheless, adverse events caused some participants to discontinue treatment.
In the ATTAIN-OSA study without PAP therapy, 12.2% of participants receiving orforglipron discontinued because of adverse events, compared with 3.8% receiving placebo.
In the study involving PAP users, the corresponding percentages were 6.8% and 0.6%.
FDA-approved GLP-1 medications also carry important warnings and precautions that should be reviewed in the current prescribing information.
For investigational therapies such as retatrutide and EloraTZP, safety continues to be evaluated through clinical research.
Why Do These Developments Matter for Peptide Research?
The latest research highlights several scientific approaches to metabolic regulation.
Retatrutide examines simultaneous activation of GLP-1, GIP, and glucagon receptors through a single peptide molecule.
EloraTZP explores the combination of amylin and incretin pathways.
Foundayo demonstrates how a non-peptide small molecule can activate GLP-1 receptors through an oral pharmaceutical formulation.
Together, these programs contribute to research involving receptor pharmacology, molecular structure, energy metabolism, and obesity-associated conditions.
For laboratories studying peptide signaling, the distinctions between these mechanisms are scientifically relevant.
However, published pharmaceutical studies cannot establish the identity, safety, or suitability of independently marketed research compounds.
Research-grade materials must be assessed independently for their intended scientific applications.
At Neuro Peptide, our educational content focuses on peptide structure, molecular signaling, and published scientific findings.
Frequently Asked Questions
What is Eli Lilly’s newest weight-loss drug in 2026?
Foundayo (orforglipron) is Eli Lilly’s newly FDA-approved oral weight-loss medicine. Other new treatments under investigation include retatrutide and EloraTZP.
What is the latest Eli Lilly weight-loss drug news?
On November 9, 2026, Eli Lilly announced Phase 3 results showing that Foundayo significantly reduced obstructive sleep apnea severity in adults with obesity or overweight.
Is Eli Lilly developing a weight-loss pill?
Yes. Foundayo is an oral GLP-1 receptor agonist that received FDA approval for chronic weight management on April 1, 2026.
Is Foundayo the same as retatrutide?
No. Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. Retatrutide is an investigational peptide acting on GLP-1, GIP, and glucagon receptors.
Has retatrutide been approved by the FDA?
No. As of November 10, 2026, retatrutide remains investigational. Eli Lilly has announced plans to submit a regulatory application in the first quarter of 2027.
What is EloraTZP?
EloraTZP is Eli Lilly’s investigational combination of eloralintide and tirzepatide. The combination targets amylin, GIP, and GLP-1 receptor pathways and has completed Phase 2b research.
Does Foundayo treat sleep apnea?
Foundayo is approved in the United States for chronic weight management, not specifically for obstructive sleep apnea as of November 10, 2026. Recent Phase 3 research reported improvements in sleep apnea, and Eli Lilly plans to seek an additional FDA indication.
Conclusion: Eli Lilly’s Weight-Loss Drug Research in 2026
Eli Lilly’s obesity research pipeline has expanded through several important developments in 2026.
Foundayo received FDA approval for chronic weight management in April, while its November 9 clinical findings provided new evidence concerning obstructive sleep apnea.
Retatrutide has continued progressing through Phase 3 research, including a recent head-to-head comparison with semaglutide.
EloraTZP has also produced Phase 2b findings that support further investigation of amylin and incretin receptor combinations.
These developments show how pharmaceutical researchers are evaluating different molecular approaches to metabolic regulation.
Future clinical studies, regulatory submissions, and safety evaluations will determine the roles these medicines may play in approved medical care.
For further educational coverage of receptor biology, experimental peptides, and scientific research, visit Neuro Peptide.
Scientific disclaimer: This article is for educational purposes only and does not constitute medical advice. Foundayo is an FDA-approved prescription medication for specific indications. Retatrutide and EloraTZP remain investigational. Neuro Peptide is not affiliated with Eli Lilly, and laboratory research compounds are not substitutes for approved medicines or investigational pharmaceutical products.